Active surveillance (AS) is an option for low-risk prostate cancer. Accurate risk assessment is paramount to select patients for definitive intervention and to avoid overtreatment. Although inaccurate, PSA and Gleason score changes remain common treatment triggers. Biopsy before AS is initiated could avoid misclassification and the need for serial biopsy.
ASJC Scopus subject areas